Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
The Fly

Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Edward Tenthoff downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $2, down from $8, after the company announced it is terminating development of zelnecirnon following recent FDA feedback on resolution of the outstanding clinical hold due to one patient with severe liver injury in the AD study. Rapt continues to develop next generation preclinical CCR4 inhibitors and is continuing to seek a partner for tivumecirnon for NSCLC, the firm noted.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App